Scientific deep-dive

Every Other Week: Stretching the Interval

Patients moved to every-other-week dosing after a plateau held their weight and body composition over 36 weeks. It is a case series with no control group, and it is the third of three different ways to use less drug.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·2 citations

There are three different ways to use less drug, and they keep getting confused. You can take a dose below the labeled range, which is microdosing and has no trials. You can step down to a lower labeled dose, which has been tested and randomized. Or you can keep the same dose and stretch the interval. The pharmacology of why that might work at all, and what the modeling behind it consists of, is in stretching doses to save money. A 2026 report looked at the third approach, and it is a case series.

What was observed

Patients who had plateaued on weekly semaglutide or tirzepatide were moved to reduced-frequency dosing at their existing dose, usually every other week, and followed for an average of 36.3 weeks.[1]

Body weight across the three time points in the case series.
PointWeight
Before treatment87.9 ± 2.4 kg
Plateau, on weekly dosing74.1 ± 2.4 kg
Maintenance, on reduced frequency72.4 ± 2.2 kg

Weight not only held but fell slightly further. Total body fat and truncal fat declined, skeletal muscle mass stabilized, and the metabolic improvements gained during weekly dosing were maintained.[1]

Why this cannot carry the weight people will put on it

A case series is a description of what happened to a group of patients someone chose to write up. There is no control group, no randomization, and no comparator arm continuing weekly dosing alongside them.

  • Selection. Clinicians move patients who are doing well onto reduced frequency. Patients doing well continue doing well. That alone could produce this entire result.
  • No counterfactual. Nobody knows what these same patients would have weighed had they stayed weekly. It could have been less.
  • Everyone had already plateaued. This says nothing about stretching the interval during active weight loss, which is when most people would want to.
  • Small and unblinded, with outcomes measured in a clinic that chose the intervention.
“Reduced-frequency dosing maintains weight” is exactly the sentence a cheaper subscription tier wants. A case series cannot supply it.

Why it is still worth knowing

The underlying idea is pharmacologically reasonable and under-tested. These drugs have long half-lives (semaglutide’s is about a week), so a fortnightly interval is not the same as a fortnight without drug. Enough remains between doses that the concept is not absurd, and the randomized dose-reduction evidence points the same general way: less drug held much of the loss.

It also matters practically. Cost is a leading reason people stop. In one US health system, cost or insurance problems were the most common recorded reason, behind almost half of the first-year discontinuations reviewed.[2] Stopping entirely produces a much worse outcome than any reduced-intensity strategy tested so far. A structured de-escalation supervised by a prescriber is a different thing from quietly stretching doses to make a vial last, and this report is an argument for studying the first properly rather than for improvising the second.

The version of this that goes wrong is unsupervised. Stretching an interval to save money, without anyone measuring what happens, is not what this describes. These patients were monitored, with body composition and metabolic markers tracked at each stage. If the appeal is affordability, that is a conversation to have out loud with a prescriber, because it is a clinical decision with a cost motive rather than the reverse.

Frequently Asked Questions

Some clinicians do it for maintenance after a plateau, and a 2026 case series reported that weight, body composition and metabolic improvements held over an average of 36 weeks. It is a case series with no control group, so it describes what happened rather than establishing that the approach works.
No, and the three get confused constantly. Microdosing means a dose below the labeled range. Dose reduction means a lower labeled dose, which has randomized evidence. This is a third thing, the same dose at a longer interval, and nobody has randomized it.
These drugs have long half-lives (semaglutide's is roughly a week), so a fortnightly interval is not a fortnight without drug. Meaningful concentration remains between doses, which makes the idea pharmacologically reasonable even though it is untested.
Unknown. Everyone in the series had already plateaued before switching, so it says nothing about stretching the interval during active weight loss, which is when most people would want to.
It is a reasonable thing to raise with a prescriber, given that cost is a leading reason people stop entirely and stopping produces a clearly worse outcome. What this report describes is supervised de-escalation with body composition and metabolic markers tracked, not stretching doses quietly to make a vial last.

References

  1. 1.Wong M, Wu A, Garhe PK, et al. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series Obesity. 2026. PMID: 41732031.
  2. 2.Gasoyan H, Butsch WS, Casacchia NJ, et al. Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice Obesity. 2025. PMID: 41039650.

A Pill to Hold What the Injection Lost

Daily oral orforglipron maintained 79.3% of weight already lost against 37.6% on placebo at a year in people coming off semaglutide, and 74.7% against 49.2% after tirzepatide. The trial had no arm that stayed on the injection, which is the question people actually have.

5 min read

Five Clicks Instead of a Quarter Milligram

One in five people on the label's titration schedule quit because of gut side effects. On a slower schedule it was one in fifty, at the same final dose, with the same results.

7 min read

What People Actually Do After Stopping

Average weight change in the year after stopping was +0.5% for people treated for obesity, and −1.3% for those treated for diabetes. That does not contradict the withdrawal trials. It answers a different question.

5 min read

Can You Lower the Dose and Keep the Weight Off?

Stepping down to 5 mg held 16.6% of body weight lost against 21.9% for staying at the full dose. But rescue therapy went from 8% to 25%, and to 67% on placebo.

6 min read

The Cardiovascular Cost of Stopping

A review argues that weight and blood sugar fluctuation are themselves cardiovascular risk factors, and that these drugs do not stabilize arteries the way statins do. It also says few data exist on hard outcomes after stopping.

5 min read

Not Taking It and Not Tolerating It

Real-world studies usually measure adherence and stopping separately, with every kind of stopping counted the same way. That merges someone whose body cannot tolerate the drug with someone not taking it reliably. A Scottish study separated them and found different predictors.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

8.1

Sesame Care

Oral orforglipron alongside the injectables

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →